A Phase 1b/2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies

Trial Profile

A Phase 1b/2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Avelumab (Primary) ; PD 360324 (Primary) ; PF 4518600 (Primary) ; Utomilumab (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms JAVELIN Medley
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Apr 2018 Planned End Date changed from 21 Feb 2020 to 18 Mar 2020.
    • 11 Apr 2018 Planned primary completion date changed from 10 Dec 2019 to 18 Mar 2020.
    • 31 Jan 2018 According to a Pfizer Inc. media release, the company has disclosed initial results from combination arm with utomilumab and avelumab in January 2018. Early signals of efficacy were insufficient to support advancing this combination into Phase 3 trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top